๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

LOCATION OF METASTATIC BREAST CARCINOMA BY A MONOCLONAL ANTIBODY CHELATE LABELLED WITH INDIUM-111

โœ Scribed by Rainsbury, R.M.; Westwood, J.H.; Coombes, R.C.; Neville, A.M.; Ott, R.J.; Kalirai, T.S.; Mccready, V.R.; Gazet, J-C.

Book ID
122646278
Publisher
The Lancet
Year
1983
Tongue
English
Weight
948 KB
Volume
322
Category
Article
ISSN
0140-6736

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Labelling of monoclonal antibodies 10B,
Labelling of monoclonal antibodies 10B, 8C, and M2A with Indium-111
โœ Raymond Reilly; Katherine Sheldon; Alexander Marks; Sylvain Houle ๐Ÿ“‚ Article ๐Ÿ“… 1989 ๐Ÿ› Elsevier Science โš– 305 KB

Monoclonal antibodies 10B, 8C and M2A were conjugated with cyclic DTPA anhydride to a substitution level of 1 2 mol DTPA/mol antibody. The DTPA-conjugated antibodies were purified by size-exclusion mini-column chromatography and labelled with ["qn]In acetate to a specific activity of 37-74kBq//~g (I

Optimum labelling of monoclonal antibody
Optimum labelling of monoclonal antibody 3El.2 with 111in using a bifunctional chelate
โœ R. R. Reilly; G. G. Ege ๐Ÿ“‚ Article ๐Ÿ“… 1987 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 379 KB

Monoclonal antibody 3E1.2 was coupled with the bifunctional chelate, cyclic DTPA anhydride, at molar ratios (cOTPAA:3E1.2) of 1:1, lO:l, 1OO:l and 1oOO:l. The desired substitution level of less than one mol of D"PA/bl of 3E1.2 was achieved at a molar ratio of 1O:l and a coupling efficiency of 9.9t3.

Prevention of renal tubule re-absorption
Prevention of renal tubule re-absorption of radiometal (indium-111) labelled Fab fragment of a monoclonal antibody in mice by systemic administration of lysine
โœ M. V. Pimm; S. J. Gribben ๐Ÿ“‚ Article ๐Ÿ“… 1994 ๐Ÿ› Springer ๐ŸŒ English โš– 252 KB

Systemic administration of lysine to mice injected with indium-111-labelled Fab fragment of a monoclonal antibody has been shown to reduce renal uptake/retention of the radiometal. This treatment should be applicable to clinical immunoscintigraphy and radioimmunotherapy with radiometal-labelled anti